Latest Accounting News

Flynn Gold Limited reported significant progress in its Tasmanian projects during the March 2025 quarter, highlighted by ongoing diamond drilling at Golden Ridge and discovery of new high-grade gold and silver-lead-zinc targets. The company secured $2.6 million in fresh capital to fund accelerated exploration.

Urbanise.com Limited reported steady Q3 FY2025 revenue with recurring income dominating, resolved a key contract dispute, and maintained positive operating cash flow for the third consecutive quarter.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Burgundy Diamond Mines has released its 2024 Mineral Resources and Ore Reserves update for the Ekati diamond mine, showing minor depletion consistent with active mining operations. The report underscores the mine’s continued operational strength and adherence to industry standards.

Origin Energy’s March 2025 quarterly report reveals an 11% drop in Australia Pacific LNG revenue due to lower volumes and prices, while gas sales and Octopus Energy’s customer base expand robustly. Renewables investments advance with key project milestones.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

ImpediMed Limited reported a record A$3.4 million revenue in Q3 FY25, bolstered by a surge in Annual Recurring Revenue and a strategic sales leadership change aimed at accelerating SOZO platform adoption.

Astral Resources has updated its Mandilla Gold Project resource to 1.43 million ounces and completed the acquisition of Maximus Resources, positioning itself for a major development milestone with a Pre-Feasibility Study due in June 2025.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% revenue decline, offset by progress in carbon capture and storage projects and emissions reductions. The company maintains a strong balance sheet while setting ambitious climate targets.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.

Castile Resources has added critical mineral bismuth as a by-product to its Rover 1 Bankable Feasibility Study, leveraging a dramatic price surge driven by Chinese export restrictions.

Energy Action Limited has posted a positive net operating cash flow of A$59,000 for the quarter ending March 31, 2025, while maintaining a robust cash balance of A$1.61 million. The company’s latest cash flow report reveals steady financing activity and prudent investment spending.